Pioneering The Preventive Care For Chronic Inflammatory Diseases (CID) Using IAP-Quantum Biotechnology

IAP-Biodefense: Oral, Gut, Urogenital and Skin

A complete platform designed to prevent and treat chronic diseases

Addressing Root Cause, Healthy Lifespan, and Longevity care

Mechanism of Action

LTA, LPS, IAP, IAPD, TLR Axis

Meet Our Awesome Team

Dr. Madhu S. Malo, MBBS, PhD

Chief Scientist

Malo, MBBS, PhD. He was an Assistant Professor in Harvard Medical School, and a Postdoc in MIT.

Dr. Biplab K. Malo, DMD

Founder and CEO, Scientist

Malo, DMD graduated from University of Pennsylvania, School of Dental Medicine in 2000.

Suresh Subbu

Technology Advisor

Suresh Subbu is a highly skilled and experienced technology executive

Robert Ferdowsmakan, DMD, MD

Advisor- clinical research in oral & maxillofacial area

Dr. Robert Ferdowsmakan is a board-certified Oral and Maxillofacial Surgeon in San Diego, CA with both and MD and DMD

Our Mission

To prevent chronic inflammatory diseases (CID)

Our Vision

To see a healthier world

Discover your IAP level

IAP in the gut is the single most important enzyme related to chronic diseases. IAP deficiency (IAPD) is defined having less than 65 unit IAP per gram of stool. Therefore, checking your IAP level is extremely important to intercept and prevent chronic diseases. Ask your primary care physician during annual check up for a STAP-Test.

Our Pipeline

IAP-Biodefense Oral:

IAP-Mouthwash® is our leading product for oral and systemic health

SGLad/pd is in progress

IAP-Toothpaste™

Pioneering in Treatment of Oral Health, Cardiovascular diseases, AD/PD, and Cancer

Two Decades of Research

§Issued patent: Diagnosis and treatment of incipient diabetes. U.S. 10,781,470 USPTO ), Inventor: MS Malo

2010

Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, Malo et el., Gut. 2010 Nov;59(11):1476-84 https://pubmed.ncbi.nlm.nih.gov/20947883/ citations: 256

2013

Intestinal alkaline phosphatase prevents metabolic syndrome in mice, Kaliannan et al. Proc Natl Acad Sci U S A. 2013 Apr 23;110(17): 7003-8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637741/

2015

A High Level of Intestinal Alkaline Phosphatase Is Protective Against Type 2 Diabetes Mellitus Irrespective of Obesity, Malo, EBioMedicine, 1December 2015, https://pubmed.ncbi.nlm.nih.gov/26844282/ citations: 87

2021

In a 5-year prospective cohort human study, Dr. Malo and his team proved, “IAP deficiency increases the risk of T2DM.” Malo et al., BMJ Open Diabetes Res Care. 2022 Jan:10(1)e002643; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796214/ The American Diabetes Association and the British Medical Journal jointed published the BMJ Open Diabetes Res Care journal article.

Our Gallery

Leadership Award

Dr. Biplab Malo – Outstanding Leadership Award | Health 2.0 Conference | USA Summer 2023

Dr. Biplab Malo, Founder & CEO of STAPGEN LLC, shares his transformative experience of being recognized with Outstanding Leadership Award at the Summer Edition of the Health 2.0 Conference, USA on July 10-12, 2023.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Stapgen

Home